Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Zynerba Pharma CS (ZYNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 170,456
  • Shares Outstanding, K 21,070
  • Annual Sales, $ 90 K
  • Annual Income, $ -39,910 K
  • 60-Month Beta 4.93
  • Price/Sales 2,016.35
  • Price/Cash Flow N/A
  • Price/Book 2.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.46
  • Number of Estimates 2
  • High Estimate -0.46
  • Low Estimate -0.46
  • Prior Year -0.91
  • Growth Rate Est. (year over year) +49.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.92 +64.43%
on 03/19/19
9.49 -14.75%
on 04/08/19
+3.25 (+67.15%)
since 03/18/19
3-Month
3.56 +127.57%
on 01/23/19
9.49 -14.75%
on 04/08/19
+4.20 (+107.97%)
since 01/18/19
52-Week
2.75 +194.18%
on 12/31/18
12.50 -35.28%
on 06/22/18
-1.87 (-18.78%)
since 04/18/18

Most Recent Stories

More News
Is Zynerba Pharmaceuticals (ZYNE) Stock Outpacing Its Medical Peers This Year?

Is (ZYNE) Outperforming Other Medical Stocks This Year?

ZYNE : 8.09 (-1.70%)
Zynerba Pharmaceuticals (ZYNE) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $8.23, marking a -0.84% move from the previous day.

ZYNE : 8.09 (-1.70%)
Widespread Clinical Studies Can Reinvigorate the Legalization Movement for Cannabis

Researchers and scientists are constantly developing new, innovative medicines to effectively treat patients. However, the cost to conduct clinical trials and then receive approval to commercialize a drug...

SRNE : 3.84 (-1.29%)
NTEC : 6.39 (+2.08%)
NLBS : 0.2020 (+1.25%)
ZYNE : 8.09 (-1.70%)
NEPT.TO : 5.38 (+4.06%)
PBIO : 3.6550 (-3.82%)
NEPT : 4.03 (+4.13%)
Will Zynerba Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Zynerba Pharmaceuticals.

ZYNE : 8.09 (-1.70%)
Consolidated Research: 2019 Summary Expectations for Okta, Zynerba Pharmaceuticals, BioXcel Therapeutics, Capital Southwest, Amber Road, and Foundation Building Materials -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Okta, Inc. (NASDAQ:OKTA), Zynerba...

FBM : 13.10 (+2.99%)
AMBR : 8.55 (-3.50%)
CSWC : 21.59 (unch)
BTAI : 9.72 (+0.93%)
OKTA : 91.94 (-0.28%)
ZYNE : 8.09 (-1.70%)
Legal Barriers Falling for the Cannabis Market's Rampant Growth

The cannabis market has begun to garner worldwide attention as more countries move to adopt cannabis legislation. Primarily, most countries are looking to adopt medical cannabis laws. Countries that have...

CLSH : 0.3168 (-0.35%)
CL.CN : 16.170 (-0.80%)
ORHOF : 8.9741 (-1.10%)
CWBHF : 20.4495 (-2.21%)
CLSH-U.CN : 0.310 (unch)
CRLBF : 12.0933 (-0.95%)
CWEB.CN : 27.350 (-1.51%)
OH.CN : 11.970 (-1.32%)
ZYNE : 8.09 (-1.70%)
NEPT.TO : 5.38 (+4.06%)
NEPT : 4.03 (+4.13%)
Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?

Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

ZYNE : 8.09 (-1.70%)
Research and Regulatory Agencies add Credibility to the Rapidly Growing CBD Market

The cannabis marketplace has become one of the fastest growing global industries, as the rapid expansion of the cannabis market is largely due to the ongoing legalization efforts in many countries. The...

ACB : 9.00 (+0.45%)
ACB.TO : 12.03 (+0.67%)
ACBFF : 8.6900 (-12.80%)
GTII.CN : 21.040 (+7.02%)
VFF : 11.92 (-4.49%)
VFF.TO : 15.99 (-4.48%)
VLLFF : 2.4000 (unch)
NLBS : 0.2020 (+1.25%)
PRAH : 94.47 (+0.36%)
ZYNE : 8.09 (-1.70%)
PBIO : 3.6550 (-3.82%)
GTBIF : 15.5949 (+5.82%)
Zynerba Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that...

ZYNE : 8.09 (-1.70%)
CBD Continues to Thrive in Both Recreational and Medical Cannabis Markets

Cannabis is a family of plants with two primary classifications, Indica and Sativa. Despite the two falling under one cannabis family, they are widely different in their biological makeup and effects....

NBEV : 5.27 (+0.19%)
WTER : 2.34 (+2.18%)
DOSE.CN : 0.780 (-2.50%)
APHA : 7.65 (-2.17%)
CIIX : 0.4700 (-2.08%)
WTER.VN : 3.110 (+1.30%)
APHA.TO : 10.25 (-2.10%)
ZYNE : 8.09 (-1.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade ZYNE with:

Business Summary

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal...

See More

Key Turning Points

2nd Resistance Point 8.56
1st Resistance Point 8.33
Last Price 8.09
1st Support Level 7.73
2nd Support Level 7.36

See More

52-Week High 12.50
Fibonacci 61.8% 8.78
Last Price 8.09
Fibonacci 50% 7.63
Fibonacci 38.2% 6.47
52-Week Low 2.75

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar